2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Emerging Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Pathogenesis, Immune Mechanism, Multi-Systemic Interactions, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

2396 Time to first fever is strongly associated with subsequent severe immune-effector cell associated neurotoxicity syndrome in relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel

Sergio Farina, MD, Daniel Raffoul2, Nicole O'Leary, NP3, Jemma Stewart4, Kerby Purcell5, Brydon Panozzo6, Anastasia Edelkina7, John F. Seymour, MBBS, PhD8, Philip Thompson, MB, BS9, Mary Ann Anderson, MBBS, FRACP, FRCPA10, Simon Harrison, MBBS, FRCPath, MRCP, PhD, FRACP11, Michael Dickinson, MBBS (Hons), DMedSci FRACP, FRCPA12, Tomas Kalincik13, Izanne Roos, MD, PhD14, Mark Raymond Dowling, PhD15
1 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, melbourne, Victoria, Australia
2 The Royal Melbourne Hospital, Melbourne, Victoria, Australia, The University of Melbourne, Melbourne, Victoria, Australia
3 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, melbourne, Victoria, Australia
4 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, melbourne, Victoria, Australia
5 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, melbourne, Victoria, Australia
6 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, melbourne, Victoria, Australia
7 Peter MacCallum Cancer Centre, Melbourne, Australia
8 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, melbourne, Victoria, Australia
9 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, melbourne, Victoria, Australia, The University of Melbourne, Melbourne, Victoria, Australia
10 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, melbourne, Victoria, Australia, The University of Melbourne, Melbourne, Victoria, Australia
11 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, melbourne, Victoria, Australia, Peter MacCallum Cancer Centre, Melbourne, Australia, The University of Melbourne, Melbourne, Victoria, Australia
12 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, melbourne, Victoria, Australia, Peter MacCallum Cancer Centre, Melbourne, Australia, The University of Melbourne, Melbourne, Victoria, Australia
13 The Royal Melbourne Hospital, Melbourne, Victoria, Australia, The University of Melbourne, Melbourne, Victoria, Australia
14 The Royal Melbourne Hospital, Melbourne, Victoria, Australia, The University of Melbourne, Melbourne, Victoria, Australia
15 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, melbourne, Victoria, Australia, Peter MacCallum Cancer Centre, Melbourne, Australia, The University of Melbourne, Melbourne, Victoria, Australia

Introduction: Axicabtagene ciloleucel (axi-cel) is now a standard-of-care treatment for relapsed/refractory large B-cell lymphoma (r/r LBCL) in second line (2L) and beyond and is the most prescribed CAR-T product in Australia. Immune effector cell-associated neurotoxicity syndrome (ICANS) is a serious adverse event that can result in significant morbidity and mortality and leads to heavy utilisation of healthcare resources. Early recognition of patients at risk of severe ICANS (Grade 3 or above) is critical to determine monitoring intensity and pre-emptive intervention decisions. Pre-infusion clinical risk factors (such as age, disease bulk and kinetics) show only modest discriminatory power in predicting those at high risk of severe cytokine release syndrome (CRS) and ICANS.  Post-infusion cytokine profiles (e.g. IL-6, MCP-1, IL-8, IFNg) have been associated with toxicity severity, but these findings have not been translated into validated predictive tests. Furthermore, We evaluated the utility of the combination of clinical risk factors and CRS onset as early predictors for subsequent severe ICANS.

Method: All patients treated with axi-cel at a single Australian centre between 01-Aug-2021 and 31-Dec-2025 were included. We recorded the timing (hours) of transitions between CRS and ICANS grades. Logistic regression (LR) and Cox proportional hazards (CoxPH) modelling was used to analyse the relationship between pre-infusion patient and disease characteristics with incidence and time of onset of sequential grades of CRS and ICANS. We then explored the relationship between time to first fever (G1 CRS, which universally preceded severe ICANS in our data), baseline patient and disease characteristics and the incidence of G3+ ICANS and univariable and multivariable analyses.

Results: 222 patients were included. The median age was 65 (range 16–85) years; 87 (39%) were female; 103 (46%) had ECOG ≥1 ; 54 (24%) received axi-cel as second-line (2L) therapy and 168 (76%) as third line or beyond (3L+); 118 (53%) were primary refractory; 160 (72%) were refractory to last therapy. Histological subtypes included diffuse large B-cell lymphoma 130 (59%), transformed follicular lymphoma 51 (23%), high grade lymphoma with MYC/BCL2 and/or BCL6 re-arrangement 27 (12%) and other 14 (6%).

The maximum grade of CRS was 0: 9 (4%), 1: 91 (41%), 2: 112 (50%), 3+: 10 (5%). The maximum grade of ICANS was 0: 77 (35%), 1: 79 (46%), 2: 23 (10%), 3+: 43 (19%). The median time to onset of first fever (≥38.0°C) was 29h (range 5–317h). On univariable analysis, only male sex (hazard ratio (HR) 1.43; 1.07–1.89) and 2L vs 3L+ therapy (HR 1.79; 1.30–2.44) were associated with earlier onset of fever. G≥3 ICANS occurred in 43 patients (19%) at a median onset of 126h (range 65–291h); all had preceding CRS. ECOG ≥1 (odds ratio (OR) 2.09; 1.03–4.06) and disease bulk ³10cm (OR 3.27; 1.38–7.74) pre-lymphodepletion were associated with G≥3 ICANS, while higher LDH, CRP, Ferritin and total metabolic tumour volume (TMTV) showed no association as continuous or categorical variables. Univariate spline analysis demonstrated a strong association between time from CAR-T infusion to first fever and subsequent occurrence of G≥3 ICANS. The OR for G≥3 ICANS was approximately halved (OR 0.51; 95% CI 0.29–0.89) for every 12-hour delay in fever onset within the first 36 hours post-infusion. Risk of G≥3 ICANS was 36% with first fever occurring within 24 hours, 19% at 24-48 hours, 6% at 48-72 hours and 5% at >72 hours. On multivariable analysis, this relationship was independent of relevant baseline variables including ECOG, tumour bulk, bridging response, LDH and TMTV.

Conclusion: Early onset of fever post-infusion is strongly associated with subsequent severe ICANS in patients with r/r LBCL treated with axi-cel and may warrant more intensive observation and/or earlier intervention with corticosteroids and anti-cytokine therapy.

Sergio Farina, MD: Johnson & Johnson - Honoraria